COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

Enrico Heffler(Humanitas University), Marco Contoli(University of Ferrara), Giacomo Malipiero(Azienda Ospedaliera Santa Maria Degli Angeli), Claudia Crimi(Marconi University), Stefano Centanni(University of Milan), Giorgio Walter Canonica(Humanitas University), Alberto Papi(University of Ferrara), Gianenrico Senna(University of Verona), Daniela Morrone(Azienda Sanitaria Locale di Asti), Giuseppe Guida(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Aikaterini Detoraki(Federico II University Hospital), Alberto Giovanni Gerli(Biomolecular Research Genomics (Italy)), Marianna Padovani(University of Ferrara), Luisa Brussino(A. O. Ordine Mauriziano di Torino), Giovanni Paoletti(Humanitas University), Francesco Blasi(University of Milan), Pierluigi Paggiaro(University of Pisa)
Allergy
August 1, 2020
10.1111/all.14532
Cited by 85

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
World Allergy Organization Anaphylaxis Guidance 2020
|World Allergy Organization Journal|2020|1.1k
Can artificial intelligence help for scientific writing?
|Critical Care|2023|795